OBJECTIVE: This project was designed to longitudinally study persons who had antibodies to hepatitis C virus (HCV) to characterise the serologic course of infection. METHODS: The subjects were 149 multitransfused patients (141 with thalassaemia major, 3 with thalassaemia intermedia, and 5 with sickle cell anaemia) who had been regularly followed up for 3 to 7 years. Sequential serum samples obtained semi-annually between January 1994 and January 2001 were tested, prospectively, by second or third generation HCV enzyme-linked immunosorbent assay (ELISA), followed by confirmatory recombinant immunoblot assay (RIBA-2 or RIBA-3). RESULTS: Of the 149 patients, 90 did not seroconvert to HCV, whereas 59 had detectable antibodies. On the basis of RIBA results in these 59 patients, 24 (41%) had persistent high antibody levels to structural and non structural HCV antigens, 11 (19%) had persistent low antibody levels, 17 (29%) showed fluctuating antibody levels, and in 5 patients (8%) there was a total or a partial disappearance of specific antibodies (seroreversion), mainly anti-core antibodies. Two patients (3%) had antibody responses that did not fit into any of these four categories. In patients with fluctuating antibody levels, there were periods ranging from 6 months to 2 years when anti-HCV antibodies could not be detected. CONCLUSION: This study shows that the antibody response to HCV in patients who receive frequent blood transfusions is very variable. Individuals who exhibit intermittent seropositivity are a challenge to diagnosis.
OBJECTIVE: This project was designed to longitudinally study persons who had antibodies to hepatitis C virus (HCV) to characterise the serologic course of infection. METHODS: The subjects were 149 multitransfused patients (141 with thalassaemia major, 3 with thalassaemia intermedia, and 5 with sickle cell anaemia) who had been regularly followed up for 3 to 7 years. Sequential serum samples obtained semi-annually between January 1994 and January 2001 were tested, prospectively, by second or third generation HCV enzyme-linked immunosorbent assay (ELISA), followed by confirmatory recombinant immunoblot assay (RIBA-2 or RIBA-3). RESULTS: Of the 149 patients, 90 did not seroconvert to HCV, whereas 59 had detectable antibodies. On the basis of RIBA results in these 59 patients, 24 (41%) had persistent high antibody levels to structural and non structural HCV antigens, 11 (19%) had persistent low antibody levels, 17 (29%) showed fluctuating antibody levels, and in 5 patients (8%) there was a total or a partial disappearance of specific antibodies (seroreversion), mainly anti-core antibodies. Two patients (3%) had antibody responses that did not fit into any of these four categories. In patients with fluctuating antibody levels, there were periods ranging from 6 months to 2 years when anti-HCV antibodies could not be detected. CONCLUSION: This study shows that the antibody response to HCV in patients who receive frequent blood transfusions is very variable. Individuals who exhibit intermittent seropositivity are a challenge to diagnosis.
Entities:
Keywords:
antibody response; hepatitis C virus; thalassaemia
Authors: J J Lefrère; S Guiramand; F Lefrère; M Mariotti; P Aumont; J Lerable; J C Petit; R Girot; L Morand-Joubert Journal: J Infect Dis Date: 1997-02 Impact factor: 5.226
Authors: R Soffredini; M Rumi; P Lampertico; A Aroldi; A Tarantino; C Ponticelli; M Colombo Journal: Am J Kidney Dis Date: 1996-09 Impact factor: 8.860
Authors: D Bresters; H L Zaaijer; H T Cuypers; H W Reesink; I N Winkel; P J van Exel-Oehlers; A A van Drimmelen; P L Jansen; C L van der Poel; P N Lelie Journal: Transfusion Date: 1993-08 Impact factor: 3.157
Authors: M Damen; H L Zaaijer; H T Cuypers; H Vrielink; C L van der Poel; H W Reesink; P N Lelie Journal: Transfusion Date: 1995-09 Impact factor: 3.157
Authors: P Farci; H J Alter; S Govindarajan; D C Wong; R Engle; R R Lesniewski; I K Mushahwar; S M Desai; R H Miller; N Ogata Journal: Science Date: 1992-10-02 Impact factor: 47.728
Authors: Gerlinde R Van de Walle; Troels K H Scheel; Joy E Tomlinson; Raphael Wolfisberg; Ulrik Fahnøe; Roosheel S Patel; Sheetal Trivedi; Arvind Kumar; Himanshu Sharma; Louise Nielsen; Sean P McDonough; Jens Bukh; Bud C Tennant; Amit Kapoor; Brad R Rosenberg; Charles M Rice; Thomas J Divers Journal: Hepatology Date: 2021-06-11 Impact factor: 17.298